)

Fennec Pharmaceuticals (FENC) investor relations material
Fennec Pharmaceuticals H.C. Wainwright 27th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Key business updates
Achieved three consecutive quarters of revenue growth, with Q2 net product sales up 33% year over year, reaching nearly $10 million.
Rebuilt commercial and medical organization, bringing in new leadership to expand market presence, especially in adolescent and young adult (AYA) segments.
Secured a global partnership with Norgine for commercialization in Europe, Australia, and New Zealand, with $43 million upfront and over $200 million in potential milestones.
PEDMARQSI launched in the UK and Germany, with further EU rollouts planned in the next year.
Japanese clinical trial results expected by year-end, targeting a market about one-third the size of Europe or the U.S.
Product and market insights
PEDMARK is the first and only FDA-approved agent to prevent cisplatin-induced hearing loss, showing about 50% reduction in hearing loss in phase III trials.
Holds strong IP protection: six U.S. Orange Book patents, seven years of U.S. exclusivity, and 10 years in Europe.
U.S. approval covers patients over one month old with localized, non-metastatic solid tumors; EU and UK approvals received in 2023.
NCCN Clinical Practice Guidelines now include a 2A endorsement for AYA patients, expanding the addressable market.
Pediatric market is highly concentrated, while the AYA market is larger and more dispersed across community centers.
Commercial execution and patient support
Organization now has 38 employees, with over half in customer-facing roles, and a new cross-functional leadership team.
Achieved over 80% reimbursement success with major insurers, supporting broad patient access.
Built strong relationships with key opinion leaders and audiologists to drive awareness and adoption.
Fennec HEARS program provides education, financial, and patient support, especially as focus expands to AYA patients.
Rebuilt support programs to ensure successful administration and reimbursement for both pediatric and AYA markets.
Next Fennec Pharmaceuticals earnings date

Next Fennec Pharmaceuticals earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage